Remitz Anita, Peltonen Essi J, Korhonen Laura, Nortamo Pekka, Iso-Mustajärvi Ilona, Prami Tuire, Oinonen Lasse, Gittens Beatrice, Von Arx Lill-Brith, Porsdal Vibeke
Department of Dermatology and Allergology at University of Helsinki, Helsinki, Finland.
Oriola, Espoo, Finland.
Acta Derm Venereol. 2025 Apr 24;105:adv41244. doi: 10.2340/actadv.v105.41244.
This observational study evaluated demographics, disease characteristics, and treatment patterns in children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) and compared comorbidities (adults only) and healthcare resource use with those of matched reference subjects without moderate-to-severe AD in Finland between 2016 and 2020. A total of 68,216 patients with moderate-to-severe AD and a reference population of 338,325 people without moderate-to-severe AD were identified and included in the study. Among children aged 0-11 years in the moderate-to-severe AD cohort, most were diagnosed with AD and were identified to have moderate-to-severe AD before they reached 4 years of age (92.4% and 79.3%, respectively). Atopic disorders and psychiatric, gastrointestinal, and other diseases were more common in adults with moderate-to-severe AD than in the reference population. Regardless of age, patients with moderate-to-severe AD had a higher number of primary and secondary healthcare visits annually compared with the reference population. Across all 3 age groups, topical corticosteroids and emollients were the 2 categories of AD medications most frequently used throughout the study period. In adults, the use of methotrexate and dupilumab increased over the course of the study. Moderate-to-severe AD affects people of all ages in Finland.
这项观察性研究评估了2016年至2020年期间芬兰中重度特应性皮炎（AD）儿童、青少年和成人的人口统计学特征、疾病特征和治疗模式，并比较了合并症（仅成人）和医疗资源使用情况与匹配的无中重度AD参考对象的情况。共识别出68216例中重度AD患者和338325名无中重度AD的参考人群并纳入研究。在中重度AD队列中0至11岁的儿童中，大多数在4岁之前被诊断出患有AD并被确定为中重度AD（分别为92.4%和79.3%）。中重度AD成人患者中特应性疾病、精神疾病、胃肠道疾病和其他疾病比参考人群更常见。无论年龄大小，中重度AD患者每年的初级和二级医疗就诊次数均高于参考人群。在所有三个年龄组中，局部用皮质类固醇和润肤剂是整个研究期间最常用的两类AD药物。在成人中，甲氨蝶呤和度普利尤单抗的使用在研究过程中有所增加。中重度AD影响芬兰所有年龄段的人群。
